Adlai Nortye Ltd. (ANL) has a MoatMap StockRank of 25/100 based on Quality (13/100), Value (35/100), and Momentum (69/100) factor scores. The current signal is SELL. Adlai Nortye Ltd., a Canadian healthcare company (likely biotech/pharma), lacks a direct and strong macro tailwind. Small-cap biotech companies are typically high-risk, R&D-intensive, and rarely fit the 'quality compounder' criteria for a concentrated portfolio seeking asset-light, high-ROIC businesses with durable moats.